SELLAS Strategy and Business Model

Executive Overview

SELLAS is a U.S.-listed clinical-stage biopharmaceutical company focused on oncology, with the sharpest emphasis on blood cancers where a small company can pursue highly targeted development programs. Its lead asset is galinpepimut-S, usually called GPS, a Wilms Tumor 1 (WT1)-targeting immunotherapy being studied in the Phase 3 REGAL trial in acute myeloid leukemia (AML) patients in second complete remission. Its second core program is SLS009, a selective cyclin-dependent kinase 9 (CDK9) inhibitor being developed in relapsed or refractory AML and other potential hematologic settings. Headquartered in New York, SELLAS took its current public-company form through the combination of the Swiss-founded SELLAS business with Galena Biopharma in 2017. As of the latest public reporting available through 2024, SELLAS had no approved products and no established commercial revenue base; its economics are driven instead by clinical milestones, regulatory progress, licensing strategy, and access to capital. That makes SELLAS less a mature operating company than a concentrated oncology development story whose strategy depends on turning a small number of differentiated assets into approval, partnership value, or eventual specialty commercialization.

SELLAS at a Glance

Logo
Common name	SELLAS
Full legal name	SELLAS Life Sciences Group, Inc.
Headquarters	New York, New York, USA
Ownership	Public company; Nasdaq-listed. No controlling shareholder is publicly disclosed in recent company filings.
Ticker	SLS
Exchange	NASDAQ
Market Cap	$1.78B
Revenue (FY2024)	#N/A
Founding / major historical milestones	Swiss predecessor founded in 2012; current Nasdaq-listed company formed through the 2017 reverse merger with Galena Biopharma; SLS009 was added through a licensing transaction with GenFleet in 2023.
Industry or industries	Biotechnology; oncology therapeutics; hematologic malignancies
Key products or services	Clinical-stage oncology therapeutics, primarily galinpepimut-S (GPS) and SLS009
Geographic footprint	U.S.-headquartered with multinational clinical-development, licensing, and outsourced vendor relationships
Business segments as officially reported	One operating focus: development of oncology therapeutics
Company website	https://www.sellaslifesciences.com/

1. What Is the Strategy of SELLAS?

Using the Playing to Win framework, SELLAS has a focused but high-risk strategy: concentrate capital on a very small oncology portfolio where one or two successful clinical programs could create outsized value. Public filings and investor materials through 2024 show a company centered on advancing late-stage and registration-oriented assets rather than building a broad discovery engine.

1a. What is the winning aspiration of SELLAS?

SELLAS appears to define winning as moving from a development-stage biotech into a commercial or partnerable oncology company by proving that its lead programs can improve outcomes in high-unmet-need blood cancers. In practical terms, the near-term aspiration is to generate approvable data for GPS in AML patients in second complete remission and to establish SLS009 as a clinically meaningful, potentially biomarker-guided therapy in relapsed or refractory AML. Because the company has no marketed products, success is measured less by current sales and more by survival data, response data, regulatory progress, and deal leverage.
1b. Where does SELLAS play?

SELLAS plays in a narrow part of oncology: hematologic malignancies and other cancer settings where a differentiated mechanism can matter and where patient populations are concentrated enough for a small company to compete. GPS targets WT1-positive cancers, with the most important current battleground being AML in second complete remission. SLS009 is aimed at relapsed or refractory AML and potentially other hematologic uses if data justify expansion. Geographically, SELLAS plays where major oncology regulatory approvals and partnering economics matter, but it does so with an outsourced operating model rather than a large owned commercial footprint.
1c. How does SELLAS plan to win?

SELLAS is trying to win through clinical differentiation, not scale. GPS is positioned around a post-remission AML setting where durable survival benefit would be valuable and direct competition is more limited than in frontline AML. SLS009 is being developed as a selective CDK9 inhibitor, with management highlighting combination use and biomarker-defined opportunities that could create a clearer regulatory and commercial niche. The company also tries to win financially by staying lean: licensing assets, outsourcing much trial execution and manufacturing, and preserving capital for the few milestones most likely to re-rate the business.
1d. What capabilities must SELLAS have in place?

The required capabilities are clinical-development execution in hematologic oncology, regulatory strategy, biomarker and translational science, manufacturing oversight through external partners, and capital-markets access. For a company of this size, relationships with key opinion leaders, investigators, contract research organizations, and contract manufacturers are especially important. SELLAS also needs disciplined portfolio management, because with only a small number of core assets, each development decision has a large impact on enterprise value.
1e. What management systems does SELLAS require?

SELLAS needs milestone-based governance rather than broad divisional bureaucracy. That includes rigorous trial oversight, independent data monitoring, board-level capital allocation, vendor-performance management, intellectual-property management, and tight cash-runway planning. In a company like SELLAS, the management system must constantly link scientific decisions to financing consequences: dose expansion, trial timing, manufacturing readiness, and partnering choices all have immediate balance-sheet implications.

2. What Are the Current Strategic Initiatives of SELLAS?

SELLAS’s publicly visible strategic agenda through 2024 is concentrated around a small number of initiatives, each tied directly to pipeline value creation.

Advance GPS through the Phase 3 REGAL study in AML. The centerpiece of SELLAS’s strategy is the registrational REGAL trial of GPS in AML patients in second complete remission. Company updates in 2024 emphasized continued study execution, interim-monitoring milestones, and progression toward the overall survival analysis that matters most for approval and valuation.
Build SLS009 into a second meaningful value driver. After licensing the asset from GenFleet in 2023, SELLAS has been advancing SLS009 in relapsed or refractory AML, including combination-based development and biomarker-oriented patient selection highlighted in company communications. This matters strategically because it reduces dependence on a single asset.
Focus on biologically defined, high-unmet-need oncology niches. SELLAS is not trying to compete broadly across all solid tumors or all blood cancers. Its development choices suggest a preference for targeted indications where a smaller trial program can still create significant strategic value if the data are strong.
Run an outsourced, capital-efficient operating model. The company continues to rely heavily on external clinical, manufacturing, and laboratory partners rather than building large internal infrastructure. That choice is consistent with preserving resources for pivotal readouts.
Maintain financing flexibility alongside clinical execution. As with many development-stage biotechs, capital strategy is part of operating strategy. SELLAS’s public actions indicate an effort to finance the company to key data catalysts while keeping open the option of future partnering or regional licensing.

3. What Is the Business Model of SELLAS?

SELLAS is best understood as a development-stage specialty oncology company, not yet a traditional revenue-producing pharmaceutical business. As of the latest public filings through 2024, it had no approved commercial products. Today, the economic model is therefore driven by research and development spending, licensing rights, financing activity, and the market value created by clinical progress.

What customers actually buy

At present, there is no marketed SELLAS therapy for physicians, hospitals, or patients to buy. If GPS or SLS009 reaches approval, the future customer offering would be a high-value oncology therapy used by specialist hematologists and oncology centers in narrow disease settings.

Recurring or repeat-driven versus one-time economics

Current economics are not recurring in the way a software subscription business is recurring. They are episodic, tied to financings, licensing terms, and development milestones. A future commercial model would still not be subscription-based; it would be repeat-driven through patient treatment cycles, ongoing new-patient flow, and potentially lifecycle expansions into additional indications.

How pricing power works

For an oncology biotech like SELLAS, pricing power would depend less on scale and more on clinical differentiation. If a therapy shows meaningful survival benefit or strong response rates in a hard-to-treat AML setting, pricing can be supported by orphan-like economics, specialist prescribing, and payer willingness to reimburse meaningful clinical value. If differentiation is weak, pricing leverage falls quickly.

Why the business mix matters

The mix between GPS and SLS009 is strategically important. GPS is the nearer-term, more registrational asset and therefore the most immediate determinant of company value. SLS009 is earlier but potentially broadens the story into precision hematology and combination therapy. In effect, GPS is the late-stage binary catalyst; SLS009 is the follow-on growth option.

What drives margin and cash generation

If SELLAS reaches commercialization, gross margins could be attractive because specialty oncology drugs typically carry manufacturing costs that are low relative to selling price. Operating margins, however, would initially depend on launch scale, medical-affairs spending, and post-approval development costs. Today, cash generation is negative and depends primarily on external financing rather than operations. That is normal for a clinical-stage biotech but makes capital access a core part of the business model.

Revenue model

The current model is effectively a combination of equity-funded drug development and potential licensing economics. The future model, if products are approved, would likely be a specialty pharmaceutical model: prescription or administered oncology therapies sold through focused channels in major markets, with the possibility of ex-U.S. partnering where a small direct commercial build-out would be inefficient.

4. What Products and Services Does SELLAS Sell?

As of 2024, SELLAS did not have approved commercial products. Its value is concentrated in a small pipeline of clinical-stage oncology programs.

Galinpepimut-S (GPS). GPS is SELLAS’s lead immunotherapy program and the company’s most strategically important asset. It targets WT1, a protein expressed in a range of cancers, and the key current development focus is AML in second complete remission through the Phase 3 REGAL study. Because it is the most advanced program, GPS is the asset most likely to determine whether SELLAS can become a commercial-stage company.
SLS009. SLS009 is a selective CDK9 inhibitor that SELLAS added through a licensing transaction with GenFleet in 2023. The program is being developed in relapsed or refractory AML, with company updates highlighting combination strategies and biomarker-oriented development. Strategically, SLS009 gives SELLAS a second mechanism and reduces single-asset concentration.
Legacy or lower-priority programs. Compared with earlier phases of the company’s history, SELLAS is now much more concentrated. The investment case and strategic profile are driven overwhelmingly by GPS and SLS009 rather than a broad bench of commercial or near-commercial assets.

5. What Are the Key Competitors or Peers of SELLAS?

Because SELLAS is still clinical-stage and its two lead assets address different parts of the AML treatment pathway, it does not have a single perfect one-for-one competitor. The most useful view is a mix of direct therapeutic substitutes, leukemia-focused peers, and modality comparables.

Bristol Myers Squibb. Through Onureg in AML maintenance, Bristol Myers Squibb is one of the clearest commercial reference points in post-remission AML care, even though the approved setting is not identical to GPS’s target setting.
AbbVie and Roche/Genentech. Venetoclax-based regimens have become central in AML treatment and shape the standard-of-care landscape against which newer agents, including SLS009 combinations, are judged.
Astellas Pharma. Astellas competes in AML through targeted therapies such as Xospata and represents a larger established hematology-oncology player with commercialization capability in leukemia.
Syndax Pharmaceuticals. Syndax is a close development-stage peer in leukemia, especially in genetically defined AML and acute lymphoblastic leukemia settings, and illustrates the competitive intensity in narrow hematology niches.
Kura Oncology. Kura’s leukemia pipeline, especially in biomarker-defined AML, makes it a relevant peer for investors and partners evaluating precision-heme oncology opportunities.
Jazz Pharmaceuticals. Jazz has a meaningful hematologic-oncology presence, including AML-related assets, and is a relevant commercial comparator in specialist cancer markets.
Novartis. Novartis is less a direct GPS competitor than a broad hematology and oncology benchmark whose scale, clinical infrastructure, and partnering reach influence the competitive environment.
BioNTech. BioNTech is better viewed as a modality comparable in cancer immunotherapy and vaccine-based oncology strategies than as a direct AML maintenance competitor, but it is relevant when thinking about immunotherapy credibility and partnership alternatives.

The key analytical point is that SELLAS competes mostly on clinical evidence in narrow niches, not on breadth of portfolio or sales-force scale.

6. What Is the Marketing Strategy of SELLAS?

SELLAS does not yet market an approved drug, so its current marketing strategy is primarily scientific, clinical, and investor-facing rather than consumer-facing. In practice, the company is marketing the credibility of its data package.

Scientific communication. Conference presentations, clinical updates, and peer engagement are central because hematologists and oncology investigators are the audiences that matter most before approval.
Key opinion leader development. In a specialist market like AML, credibility with leading leukemia physicians and trial investigators is more valuable than broad brand advertising.
Investor communications. For a pre-revenue biotech, capital access depends partly on how effectively the company explains data, trial design, and regulatory path to investors.
Future commercialization focus. If GPS or SLS009 is approved, the likely marketing model would be narrow and evidence-heavy: medical affairs, payer evidence, specialist physician education, and targeted field promotion rather than mass-media campaigns.

So far, marketing appears to be a supporting capability. The primary differentiator is still trial data, not brand spend.

7. What Are the Key Customer Segments of SELLAS?

SELLAS currently has no approved products, so it does not yet serve revenue-producing customer segments in the usual pharmaceutical sense. Its future customer map is relatively concentrated.

Hematologists and oncologists. These specialists are the key prescribers in AML and would be the primary commercial decision-makers if GPS or SLS009 reaches market.
Academic cancer centers and major community oncology networks. Many AML patients are treated in concentrated specialist settings, which means the future prescriber base is relatively focused.
Hospitals, specialty pharmacies, and infusion sites. Depending on final product format and label, these channels would matter for dispensing, administration, and reimbursement flow.
Payers. Commercial insurers, Medicare-related reimbursement channels, and other payers are economic gatekeepers in oncology and would strongly influence access and uptake.
Potential licensing or regional commercialization partners. Before or alongside a full launch, ex-U.S. or regional partners can be economically important counterparties for a company of SELLAS’s size.

The important point is concentration: SELLAS is not diversified across many customer groups. Its opportunity is highly focused in hematologic oncology.

8. What Is the Sales Model of SELLAS?

Today, SELLAS has no conventional product sales model because it has no marketed product. Its current go-to-market activity is clinical and strategic rather than commercial: managing trial sites, engaging investigators, communicating data, and exploring partnerships.

If GPS or SLS009 is approved, the most plausible sales model would be a focused specialty-heme commercial structure. AML treatment is concentrated among a relatively small number of specialist centers and physicians, so SELLAS would not need a mass-market field force. A compact U.S. sales and medical team could be viable for a narrow label, while ex-U.S. commercialization could be handled through licensing or regional partners. That approach would preserve capital and fit the company’s scale.

Channel structure would matter in several ways:

Growth: A concentrated channel can accelerate early uptake if top treatment centers are persuaded by the data.
Pricing: Specialty positioning usually supports better pricing than broad primary-care distribution.
Customer intimacy: Small specialist markets reward deep clinical engagement and strong medical-affairs execution.
Consultant opportunity: Because the channel is focused, outside experts can materially help with launch sequencing, account targeting, and payer strategy without the cost of a large permanent team.

9. In What Geographies Does SELLAS Operate?

SELLAS is headquartered in New York and listed in the United States, but its operating footprint is broader than its office footprint. Like many small biotechs, it uses a distributed model that combines a lean corporate center with global external partners.

United States. The U.S. is the center of corporate management, public-company reporting, and likely the most important future commercial market.
Europe. SELLAS’s roots include a Swiss predecessor, and European relationships remain relevant from a clinical, regulatory, and corporate-history perspective.
Asia-linked partnerships. The 2023 SLS009 transaction with GenFleet shows that SELLAS is willing to source pipeline assets through cross-border licensing.
Multinational clinical development. The company operates through trial sites, laboratories, and development vendors that may span multiple countries even though SELLAS itself does not own a large physical network.

SELLAS does not operate like a manufacturing-heavy pharma company with a visible global plant base. Its geographic model is asset-light, partner-enabled, and centered on clinical development.

10. Who Are the Owners of SELLAS?

SELLAS is a publicly traded company on Nasdaq under the ticker SLS. Based on recent public filings through 2024, ownership appears to be dispersed rather than controlled by a parent company, government entity, or single dominant shareholder. The shareholder base typically consists of a mix of specialist healthcare investors, other institutional holders, retail shareholders, and insiders such as executives and directors. Because SELLAS has relied on periodic financings, the ownership mix can change materially over time. No controlling stake is prominently disclosed in recent company materials.

11. How Is SELLAS Organized?

SELLAS appears to operate as a single focused oncology business rather than a multi-division pharmaceutical group. In practical terms, the organization is built around functions, not brands or geographic business units.

Pipeline leadership. Capital and management attention are concentrated on GPS and SLS009.
Clinical and medical functions. Trial design, site oversight, safety monitoring, biomarker work, and regulatory interactions are core operating activities.
Chemistry, manufacturing, and controls oversight. Even with outsourced manufacturing, internal oversight is needed to manage quality, supply, and regulatory compliance.
Business development and corporate functions. Licensing, investor relations, legal, finance, and public-company governance are important because external capital and partnerships are strategic assets.

There is no meaningful evidence of a broad commercial division, a consumer business, or multiple reportable industry segments. SELLAS is organized for pipeline progression, not for portfolio complexity.

12. How Does SELLAS Operate?

Day to day, SELLAS operates like a lean oncology drug developer. It creates value by selecting promising assets, designing clinical programs, managing outside vendors, generating data, and converting that data into regulatory and strategic options.

The operating model typically includes the following activities:

Asset sourcing and prioritization. SELLAS adds programs through internal development and licensing rather than a broad in-house discovery machine.
Clinical trial execution. The company works with contract research organizations, investigators, and sites to enroll patients, manage protocols, collect data, and maintain trial quality.
Manufacturing oversight. Clinical drug supply is usually outsourced, but SELLAS still must control specifications, batch availability, quality systems, and regulatory documentation.
Regulatory engagement. Interactions with the U.S. Food and Drug Administration and, where relevant, other regulators are central to trial design and approval planning.
Capital management. Because operations are not self-funding, financing is inseparable from execution.

The main bottlenecks are typical for a small biotech but especially important here: patient enrollment in specialized AML settings, dependence on third-party vendors, manufacturing readiness for late-stage trials, and the need to fund operations long enough to reach value-defining readouts.

13. What Are the Growth Opportunities for SELLAS?

SELLAS’s growth opportunities are concentrated but potentially meaningful if clinical data are positive.

Most plausible growth paths

GPS approval in AML. The clearest opportunity is successful Phase 3 data from REGAL leading to approval in AML patients in second complete remission. That would transform SELLAS from a development story into a commercial-stage or highly partnerable company.
SLS009 in biomarker-defined AML. If SLS009 continues to show encouraging activity in selected patient subsets or rational combinations, it could create a second registration path and diversify the portfolio.
Lifecycle expansion. Positive data could support study of GPS in additional WT1-positive settings or of SLS009 in adjacent hematologic malignancies, though those opportunities depend on resource availability and clinical evidence.
Partnership and licensing economics. Strong data can create growth without full self-commercialization by enabling ex-U.S. partnerships, co-development deals, or other strategic transactions.
Improved financing terms. For a biotech of this size, better data can itself be a growth opportunity because it lowers the cost of capital and expands strategic choice.

Main constraints

Binary clinical risk. With only a few core programs, disappointing data would have an outsized effect.
Financing and dilution. SELLAS must continue funding development before it has operating cash flow.
Competitive pressure in AML. The AML treatment landscape evolves quickly, so trial timing and differentiation matter.
Execution risk. Enrollment, manufacturing, vendor reliability, and regulatory alignment can all affect value realization.

14. What Is the History of SELLAS?

SELLAS traces its roots to the Switzerland-based biotech SELLAS Life Sciences Group AG, which was founded in 2012. The company has been shaped for years by Chief Executive Officer Angelos Stergiou, M.D., who has been closely associated with building the current oncology-focused strategy.

2012: The Swiss predecessor was established to develop oncology immunotherapy assets, including what became the GPS program.
2017: SELLAS became publicly listed through a reverse merger with Galena Biopharma, after which the combined company adopted the SELLAS name.
2018-2022: The company increasingly concentrated its strategy on a narrower oncology pipeline, with GPS emerging as the lead value driver.
2023: SELLAS expanded its pipeline by licensing GFH009 from GenFleet and renaming the asset SLS009, adding a selective CDK9 inhibitor to the portfolio.
2024: The company’s public narrative remained centered on Phase 3 progress for GPS and clinical expansion for SLS009.

The defining historical theme is strategic narrowing: SELLAS has evolved into a more concentrated oncology developer whose identity now rests mainly on two programs rather than a broad portfolio.

15. What Are the Key Suppliers to SELLAS?

For SELLAS, the most important suppliers are not commodity raw-material vendors but specialist development and manufacturing partners. That is typical for a small biotech with an outsourced model.

Contract research organizations. These partners help run trials, manage data, monitor sites, and support regulatory execution.
Contract development and manufacturing organizations. They manufacture clinical material under current Good Manufacturing Practice requirements and are critical for both trial continuity and eventual filing readiness.
Central laboratories and biomarker-testing providers. These matter especially for hematologic oncology programs that depend on consistent assay quality and patient stratification.
Specialized logistics providers. Clinical material has to move reliably among manufacturers, depots, and trial sites.
Clinical sites and investigator networks. Not suppliers in the classic procurement sense, but operationally they are essential external partners in patient access and study execution.

High-level company filings do not prominently identify many specific vendors, which is common. Strategically, supplier structure matters because a delay at a single qualified manufacturer or laboratory can push back trial timelines and therefore financing needs.

16. What Are the Key Assets of SELLAS?

SELLAS is not asset-heavy in the industrial sense of owning large factories or fleets. Its decisive assets are mostly intangible and clinical.

Rights to GPS and SLS009. These two programs are the company’s core value-bearing assets.
Intellectual property and know-how. Patents, licenses, formulation knowledge, and clinical-development know-how are central barriers to imitation.
Clinical data packages. For a company at this stage, trial results are strategic assets because they determine regulatory path, partnering leverage, and valuation.
Regulatory work product. IND-related documentation, manufacturing files, safety databases, and agency interactions accumulate value over time.
Public-market access. Nasdaq listing and the ability to raise capital are practical strategic assets for a clinical-stage biotech.

In other words, SELLAS’s most important assets sit in the pipeline, the data, and the rights around them, not in a large owned physical footprint.

17. What Is the R&D Strategy of SELLAS?

R&D is the center of SELLAS’s strategy. The company does not appear to be building a broad discovery platform; instead, it is pursuing a focused development strategy around a small number of oncology assets where proof of efficacy could create registration and partnership value.

Concentrate resources on a few programs. SELLAS’s R&D model favors depth over breadth, with GPS and SLS009 receiving most of the strategic attention.
Pursue registration-oriented clinical paths. GPS is already in a Phase 3 setting, which shows that SELLAS is willing to spend R&D dollars where the path to approval is most visible.
Use mechanism-led patient selection. SLS009 development suggests a preference for biomarker-informed or biologically defined subgroups rather than broad undifferentiated enrollment.
Build through licensing as well as internal advancement. The addition of SLS009 from GenFleet shows that external innovation sourcing is part of the R&D strategy.
Outsource execution, keep decisions internal. Much experimental work is performed through external partners, but the portfolio decisions, study strategy, and regulatory choices remain core internal responsibilities.

This R&D strategy fits SELLAS’s scale. It avoids the fixed cost of a large discovery organization while keeping the company exposed to high-value data catalysts.

18. What Is the Finance Strategy of SELLAS?

SELLAS’s finance strategy is fundamentally about funding the company to value-inflecting data. Because it has no established product revenue, capital allocation and financing choices are central strategic tools, not back-office issues.

Prioritize spending on lead programs. Cash must be directed mainly to GPS and SLS009 rather than to broad infrastructure or diversification.
Stay lean operationally. The outsourced model helps limit fixed costs and delays the need for a large commercial build-out until data justify it.
Use capital markets pragmatically. As with many clinical-stage biotechs, equity-linked financing has been an important source of funding. That makes timing and investor communication highly strategic.
Keep partnering optionality open. If data strengthen, licensing or regional partnerships can provide less-dilutive capital than repeated equity issuance.
No mature-company capital return logic. There is no dividend or buyback thesis here; available capital is for development, regulatory progression, and corporate survival.

The main finance constraint is straightforward: SELLAS must balance dilution risk against the need to keep advancing trials. In a small biotech, that balance often determines how much of the asset value existing shareholders ultimately keep.

19. How Companies Like SELLAS Leverage Independent Consultants through Umbrex

Umbrex has grown a global community of over 8,000 independent management consultants based in more than 50 countries. These consultants are alums of McKinsey, Bain, BCG, and other top consulting firms. Companies like SELLAS use Umbrex when they need top-tier strategic or operational talent without hiring a full consulting team and its associated overhead. For a focused biotech with a small internal staff, that model can be especially useful around major clinical, partnering, financing, and launch milestones.

Commercial-readiness planning for GPS. Build a practical launch blueprint for AML in second complete remission, including treatment-center targeting, field-force sizing, and launch sequencing assumptions.
Pricing and market-access strategy. Develop payer narratives, value dossiers, and reimbursement scenarios for a niche hematology product if GPS or SLS009 approaches approval.
Indication prioritization for SLS009. Assess which biomarker-defined AML subsegments or adjacent hematologic indications offer the best balance of speed, probability of success, and commercial value.
Partnering strategy and deal support. Run ex-U.S. licensing screens, prepare partner lists, support management presentations, and model alternative deal structures.
Clinical-operations PMO support. Create milestone dashboards and governance routines for contract research organizations, labs, and manufacturers so management can spot delays earlier.
Portfolio and capital-allocation scenario planning. Help the board and management compare pathways such as self-commercialization, regional partnering, or broader strategic alternatives after major data releases.
KOL and account mapping. Identify the highest-value leukemia centers, referral networks, and prescriber clusters that would matter most in a focused AML launch.
CMC and clinical-supply risk assessment. Evaluate outsourced manufacturing dependencies, secondary-source options, and readiness gaps that could delay a filing or launch.
Investor and strategic narrative refinement. Translate complex clinical data into a clear equity story or partner story without changing the underlying science.
Operating-model design for a post-data company. Define what SELLAS should keep in-house versus outsource across medical affairs, market access, finance, business development, and launch operations if a program succeeds.